OncLive TV

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer.

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of vaccines for patients with cervical cancer.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses genetic testing for patients with gynecologic cancers.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses liquid biopsies in lung cancer.

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.